Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.
atopic dermatitis
cutaneous adverse events
dupilumab
safety
skin reactions
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
10
02
2023
received:
03
01
2023
accepted:
20
02
2023
medline:
3
7
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL-13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real-life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real-world experiences. The authors' aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real-world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23 ± 19.66 years [range, 18-91 years]) who had received dupilumab for a minimum of 1 month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31 ± 21.26 months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91 ± 15.34 years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alopecia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty-one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.
Identifiants
pubmed: 36914982
doi: 10.1111/1346-8138.16764
doi:
Substances chimiques
dupilumab
420K487FSG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-887Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-48.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287-303.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083-101.
Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82:1328-36.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:908-19.
Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Gurioli C, et al. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis [published online ahead of print, 2022 Oct 12]. J Eur Acad Dermatol Venereol. 2022;37:e384-8.
Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V, et al. Dupilumab treatment in children aged 6-11 years with atopic dermatitis: a multicentre, real-life study. Paediatr Drugs. 2022;24:671-8.
Patruno C, Potestio L, Scalvenzi M, Battista T, Raia F, Picone V, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat. 2022;33:3028-33.
Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:139-47.
Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9:1389e92.e2.
Nettis E, Bonzano L, Patella V, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020;30:201-4.
Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, OʼDriscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond). 2021;35:3277-84.
Napolitano M, Di Guida A, Fabbrocini G, Patruno C. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-center experience. Dermatol Ther. 2021;34:e15059.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31-44.
Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469-79.
Wu S, Wang H. Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials. Postepy Dermatol Alergol. 2022;39:601-10.
Kamata M, Tada Y. A literature review of real-world effectiveness and safety of Dupilumab for atopic dermatitis. JID Innov. 2021;1:100042.
Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:62-9.e1.
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31:606-14.
Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86:628-36.
de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 2018;178:1220-1.
Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84:1339-47.
Chipalkatti N, Lee N, Zancanaro P, Dumont N, Donovan C, Rosmarin D. Dupilumab as a treatment for allergic contact dermatitis. Dermatitis. 2018;29:347-8.
Johnson H, Adler BL, Yu J. Dupilumab for allergic contact dermatitis: an overview of its use and impact on patch testing. Cutis. 2022;109:265-7.
Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86:708-9.
Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther. 2019;32:e13142.
Napolitano M, Caiazzo G, Fabbrocini G, Balato A, Di Caprio R, Scala E, et al. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment. Br J Dermatol. 2021;184:341-3.
Casale F, Nguyen C, Dobry A, Smith J, Mesinkovska NA. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis. Australas J Dermatol. 2022;63:394-7.
Russo F, Provvidenziale L, Bruzziches F, Fiorani D, Santi F, Lamberti A, et al. Psoriasis-like eruption triggered by Dupilumab therapy. Dermatitis. 2021;32:e147-8.
Jaulent L, Staumont-Sallé D, Tauber M, Paul C, Aubert H, Marchetti A, et al. Nosbaum a; for GREAT research group. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort. J Eur Acad Dermatol Venereol. 2021;35:e296-7.
Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM, et al. Early and long-term effects of Dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Invest Dermatol. 2021;141:1943-53.e13.
Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fournié P, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62:519-33.
Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol. 2021;148:198-201.
Barroso-García B, Rial MJ, Molina A, Sastre J. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol. 2018;28:420-1.
Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4:143-4.
Yazdanyar S, Jemec GBE. Alopecia areata after treatment with dupilumab. Dermatitis. 2019;30:175-6.
Salgüero-Fernández I, Gonzalez de Domingo MA, Suarez D, Roustan-Gullón G. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol. 2019;44:e41-3.
Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2019;5:54-6.
Patruno C, Napolitano M, Ferrillo M, Fabbrocini G. Dupilumab and alopecia: a Janus effect. Dermatol Ther. 2019;5:e13023.
Barbarin C, Hosteing S, Nosbaum A, Allouchery M, Celerier P. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol. 2019;29:542-3.
Penzi LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154:1358-60.
Darrigade A-S, Legrand A, Andreu N, Jacquemin C, Boniface K, Taïeb A, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018;179:534-6.
Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges. 2019;17:1278-80.
Alniemi DT, McGevna L. Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis. JAAD Case Rep. 2019;5:111-2.
Uchida H, Kamata M, Watanabe A, Agematsu A, Nagata M, Fukaya S, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol. 2019;99:675-6.
Call JE, Sahni S, Zug KA. Effectiveness of dupilumab in the treatment of both atopic dermatitis and alopecia universalis. Clin Case Rep. 2020;8:1337-9.
Babino G, Fulgione E, D'Ambra I, Calabrese G, Alfano R, Argenziano G. Rapid hair regrowth induced by dupilumab in a patient affected by alopecia totalis of 28 years' duration: clinical and dermoscopic features. Dermatol Ther. 2020;33:e13582.
Harada K, Irisawa R, Ito T, Uchiyama M, Tsuboi R. The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol. 2020;183:396-7.
Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020;6:1286-7.
Muto J, Yoshida S, Doi C, Habu M, Sayama K. Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: a Japanese case report. J Dermatol. 2021;48:e72-3.
Kageyama R, Ito T, Hanai S, Morishita N, Nakazawa S, Fujiyama T, et al. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci. 2021;22:2618.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2022;77:897-906.
Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017;76:274-80.e1.
Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of mycosis Fungoides following Administration of Dupilumab for misdiagnosed atopic dermatitis. Acta Derm Venereol. 2019;99:818-9.
Hollins LC, Wirth P, Fulchiero GJ Jr, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106:E8-11.
Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83:197-9.
Miyashiro D, Vivarelli AG, Gonçalves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther. 2020;33:e13880.
Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72:992-1002.
Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156:1086-97.
Meyer N, Mazereeuw-Hautier J, Launay F, Lamant L, Paul C. Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge? Dermatology. 2009;218:168-71.
Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: a systematic review [published online ahead of print, 2022 Sep 8]. Int J Dermatol. 2022. https://doi.org/10.1111/ijd.16388
Elston DM. Dupilumab and cutaneous T-cell lymphoma. J Am Acad Dermatol. 2020;83:33-4.
Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125:2798-805.
Hashimoto M, Miyagaki T, Komaki R, Takeuchi S, Kadono T. Development of nodular lesions after Dupilumab therapy in Erythrodermic mycosis Fungoides with Interleukin-13 receptor alpha2 expression. Acta Derm Venereol. 2022;24:adv00766.